MLICM
PACB icon

Metropolitan Life Insurance Company (MetLife)’s Pacific Biosciences PACB Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,666
Closed -$43.7K – 1498
2024
Q1 		$43.7K Sell
11,666
-2,856
-20% -$16.7K ﹤0.01% 1477
2023
Q4 		$142K Hold
14,522
– – 0.01% 905
2023
Q3 		$121K Buy
14,522
+754
+5% +$8.62K 0.01% 908
2023
Q2 		$183K Buy
13,768
+389
+3% +$4.73K 0.01% 712
2023
Q1 		$155K Sell
13,379
-534
-4% -$5.31K 0.01% 769
2022
Q4 		$114K Buy
13,913
+1,973
+17% +$17K 0.01% 981
2022
Q3 		$69.3K Sell
11,940
-1,739
-13% -$9.98K ﹤0.01% 1240
2022
Q2 		$60.5K Buy
13,679
+1,735
+15% +$10.5K ﹤0.01% 1375
2022
Q1 		$109K Sell
11,944
-39,486
-77% -$455K ﹤0.01% 1147
2021
Q4 		$1.05M Hold
51,430
– – 0.01% 924
2021
Q3 		$1.31M Sell
51,430
-1,349
-3% -$40K 0.02% 776
2021
Q2 		$1.85M Buy
52,779
+4,712
+10% +$137K 0.03% 564
2021
Q1 		$1.6M Sell
48,067
-1,496
-3% -$52.4K 0.02% 641
2020
Q4 		$1.29M Buy
49,563
+2,925
+6% +$49.7K 0.02% 723
2020
Q3 		$460K Buy
46,638
+270
+0.6% +$1.55K 0.01% 1276
2020
Q2 		$160K Buy
46,368
+431
+0.9% +$1.47K ﹤0.01% 1953
2020
Q1 		$141K Sell
45,937
-327
-0.7% -$1.34K ﹤0.01% 1809
2019
Q4 		$238K Buy
46,264
+7,310
+19% +$37.2K ﹤0.01% 1793
2019
Q3 		$201K Sell
38,954
-4,015
-9% -$22.5K ﹤0.01% 1877
2019
Q2 		$260K Buy
42,969
+2,300
+6% +$16.1K ﹤0.01% 1722
2019
Q1 		$294K Sell
40,669
-2,088
-5% -$15.1K 0.01% 1650
2018
Q4 		$316K Buy
42,757
+1,079
+3% +$6.84K 0.01% 1517
2018
Q3 		$225K Hold
41,678
– – ﹤0.01% 1920
2018
Q2 		$148K Buy
41,678
+7,052
+20% +$19.6K ﹤0.01% 2125
2018
Q1 		$71K Buy
34,626
+16,319
+89% +$42.4K ﹤0.01% 2414
2017
Q4 		$48K Buy
+18,307
New +$64.1K ﹤0.01% 2465
2017
Q3 		– Sell
-59,018
Closed -$210K – 2509
2017
Q2 		$210K Hold
59,018
– – ﹤0.01% 2308
2017
Q1 		$305K Sell
59,018
-269
-0.5% -$1.32K ﹤0.01% 1988
2016
Q4 		$225K Hold
59,287
– – ﹤0.01% 2286
2016
Q3 		$531K Buy
59,287
+5,613
+10% +$46.9K ﹤0.01% 1670
2016
Q2 		$378K Buy
53,674
+3,084
+6% +$28.2K ﹤0.01% 1873
2016
Q1 		$430K Buy
50,590
+8,828
+21% +$86.8K ﹤0.01% 1674
2015
Q4 		$548K Hold
41,762
– – ﹤0.01% 1569
2015
Q3 		$153K Buy
41,762
+3,903
+10% +$19.1K ﹤0.01% 2458
2015
Q2 		$218K Sell
37,859
-4,697
-11% -$27.2K ﹤0.01% 2341
2015
Q1 		$249K Hold
42,556
– – ﹤0.01% 1942
2014
Q4 		$334K Hold
42,556
– – ﹤0.01% 2049
2014
Q3 		$209K Hold
42,556
– – ﹤0.01% 2336
2014
Q2 		$263K Hold
42,556
– – ﹤0.01% 2311
2014
Q1 		$228K Hold
42,556
– – ﹤0.01% 2378
2013
Q4 		$223K Hold
42,556
– – ﹤0.01% 2392
2013
Q3 		$235K Buy
+42,556
New +$148K ﹤0.01% 2296

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $7.59B AUM 23.44% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s PACB Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Pacific Biosciences (PACB) in Q2 2024, closing a stake of 11,666 shares — an estimated $43.7K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in PACB in Q3 2013 and held it in 42 quarters. The position peaked at $1.85M in Q2 2021. 228 funds tracked by Wall St. Rank hold PACB as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Pacific Biosciences position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 11,666 Pacific Biosciences shares in Q2 2024, an estimated $43.7K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Pacific Biosciences in Q3 2013 and held it in 42 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Pacific Biosciences position peaked at $1.85M in Q2 2021.
  • 228 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.